Asceneuron Secures $100 Million in Series C Funding for Dementia Asset Development

1. Funding Amount: Asceneuron has raised $100 million in a series C funding round.
2. Lead Investor: The funding round was led by Novo Ventures.
3. Purpose: The funds will be used to advance the development of Asceneuron's dementia asset.
4. Company Focus: Asceneuron is focused on developing treatments for dementia and other neurological disorders.
5. Recent Milestones: Asceneuron has joined the Critical Path for Alzheimer's Disease Consortium and has made significant progress in its research and development efforts.